"Carmustine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
| Descriptor ID |
D002330
|
| MeSH Number(s) |
D02.654.692.247 D02.948.594.247
|
| Concept/Terms |
Carmustine- Carmustine
- BCNU
- N,N'-Bis(2-Chloroethyl)-N-Nitrosourea
- 1,3-Bis(2-Chloroethyl)-1-Nitrosourea
- FIVB
|
Below are MeSH descriptors whose meaning is more general than "Carmustine".
Below are MeSH descriptors whose meaning is more specific than "Carmustine".
This graph shows the total number of publications written about "Carmustine" by people in this website by year, and whether "Carmustine" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Carmustine" by people in Profiles.
-
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol. 2007 Feb 01; 25(4):399-404.
-
Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice. Carcinogenesis. 2007 May; 28(5):1111-6.
-
A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol. 2006 Nov; 58(5):634-9.
-
Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities. J Pharmacol Exp Ther. 2005 Dec; 315(3):1247-55.
-
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol. 2002 May 01; 20(9):2277-83.
-
Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors. Bone Marrow Transplant. 1998 Mar; 21(6):569-76.
-
Long-term survival after autologous bone marrow transplantation for metastatic breast carcinoma. South Med J. 1995 Mar; 88(3):320-6.
-
Repair of O6-ethylguanine in DNA protects rat 208F cells from tumorigenic conversion by N-ethyl-N-nitrosourea. Proc Natl Acad Sci U S A. 1990 Dec; 87(24):9883-7.
-
High-dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors. J Clin Oncol. 1988 Aug; 6(8):1314-20.
-
Immunotherapy with neuraminidase-treated cells and bacillus Calmette-Guerin. Surgery. 1976 Feb; 79(02):202-8.